Scholars@Duke publication: Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.

Publication , Journal Article

Patel, SS; Lally, DR; Hsu, J; Wykoff, CC; Eichenbaum, D; Heier, JS; Jaffe, GJ; Westby, K; Desai, D; Zhu, L; Khanani, AM

Published in: Eye (Lond)

December 2023

Eye (Lond)

1476-5454

December 2023

3705

England

APA

Chicago

ICMJE

MLA

NLM

Patel, S. S., Lally, D. R., Hsu, J., Wykoff, C. C., Eichenbaum, D., Heier, J. S., … Khanani, A. M. (2023). Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond), 37(17), 3705. https://doi.org/10.1038/s41433-023-02548-2

Patel, Sunil S., David R. Lally, Jason Hsu, Charles C. Wykoff, David Eichenbaum, Jeffrey S. Heier, Glenn J. Jaffe, et al. “Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial.” Eye (Lond) 37, no. 17 (December 2023): 3705. https://doi.org/10.1038/s41433-023-02548-2.

Patel SS, Lally DR, Hsu J, Wykoff CC, Eichenbaum D, Heier JS, Jaffe GJ, Westby K, Desai D, Zhu L, Khanani AM. Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial. Eye (Lond). 2023 Dec;37(17):3705.